Sprong RC, Winkelhuyzen-Janssen AM, Aarsman CJ, van Oirschot JF, van der Bruggen T, van Asbeck BS
The result is an increased energy expenditure
Each has its unique properties and uses
placebo on the time to occurrence of a composite cardiovascular outcome (nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, hospitalization or urgent visit due to heart failure) and a composite renal outcome (end-stage kidney disease, 40% sustained decline in eGFR, cardiovascular death or renal death) in 10,000 individuals with atherosclerotic cardiovascular disease and/or CKD
Tesamorelin has the strongest evidence for reducing visceral abdominal fat in adults with HIV-associated lipodystrophy, while GLP-1/GIP medications such as semaglutide and tirzepatide are generally stronger options for overall weight loss